In August 2018, Teva had received approval for the first generic versions of EpiPen and EpiPen Jr for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Epinephrine Injection, 0.15mg (Auto-Injector) is indicated for patients who weigh 15 to 30kg; the 0.3mg strength is approved for patients weighing ≥30kg.
Epinephrine acts on both alpha- and beta-adrenergic receptors. Its action on alpha-adrenergic receptors reduces the vasodilation and vascular permeability that occurs during anaphylaxis. Its action on beta-adrenergic receptors causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis. When administered subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.
“We’re pleased to provide access to Epinephrine Injection (Auto-Injector) in 2 strengths for patients who may experience life-threatening allergic emergencies,” said Brendan O’Grady, EVP and Head of North America Commercial. “We will continue working to ensure availability of both strengths in the US and plan to accelerate production to meet the urgent need for this medicine.”
The Wholesale Acquisition Cost for a 2-pack supply is $300.
For more information visit tevapharma.com.
This article originally appeared on MPR